Saturday April 25, 2009: 6-9 pm in Fairfax, VA – Chronic fatigue syndrome (CFS): Is oxygen the problem and why? A four-part treatment protocol
• By Dr. Paul Cheney, MD, PhD – ME/CFS & Environmental Illness Expert of The Cheney Clinic in Asheville, NC
• Hosted by the Northern Virginia CFS/FMS Support Group and co-sponsored by the CFS & FM Support Group of Dallas/Fort Worth, Texas.
The NOVA CFS/FMS Support Group website offers:
• Location, maps and directions
• Registration and contact info - NOVA Leader Elly Brosius at (703) 968-9818 or email@example.com; Andrea at (301) 718-9326 or firstname.lastname@example.org
And the following news release summarizing Dr. Cheney’s findings, with links to more info:
“In addition to presenting a broad overview of CFS including important principles, case definition, clinical findings, objective data, key medical literature, Dr. Cheney will present on oxygen toxicity as well as his latest four-part treatment protocol:
Oxygen Toxicity as a Controlling Factor for CFS
This section of the presentation will focus on the research finding of nearly 100% toxicity in CFS patients when oxygen is administered. Dr. Cheney will present evidence that:
• Patients categorized according to increasingly powerful treatment protocols were transformed to an increasingly oxygen tolerant state.
• The most powerful treatment protocol was also associated with significant overall clinical improvement.
• Conclusions drawn from this are CFS is an oxygen toxic state, oxygen toxicity status appears to determine outcome in therapeutic trials, and oxygen toxicity is key to this illness.
• These findings appear to force a narrowing of potential causes of CFS because whatever pathophysiology one puts forth must explain universal oxygen toxicity in CFS.
• Dr. Cheney will also present recent evidence of the likely cause of this oxygen toxicity.
For more: "Oxygen Toxicity as a Locus of Control for CFS"
Cell Associated Therapy for Chronic Fatigue Syndrome: Is this the Next Frontier?
Dr. Cheney will discuss the use of low molecular weight (LMW), mammalian tissue derived peptides as therapeutic agents when applied to the skin using novel transdermal gels. These LMW peptides are known to control gene expression and can shift organ function toward normal.
Data will be presented from a one-year prospective trial in CFS using these LMW peptides which produced significant improvement in function.
Therapy with LMW peptides from cell associated, mammalian tissue homogenates appears to offer a significant benefit in CFS, especially where it counts the most, namely, the functioning of the patient. (or ... namely, the patients' ability to do more and feel better.)
For more: "Cell Associated Therapy for Chronic Fatigue Syndrome: Is this the Next Frontier?"
Please do not wear scented products.
Event will be video taped for possible future DVD sales.